namde2 | Ho Chi Minh

Gerbing biedt een breed scala aan 12 volt verwarmde handschoenen aan. Deze zijn eenvoudig aan te sluiten op een 12 volt accu van een voertuig door middel van de accu-aansluitkabel. Ook zijn ze aan te sluiten op onze 12 volt draagbare batterijen waardoor onze verwarmde handschoenen ook gebruikt kunnen worden voor willekeurige outdoor activiteiten. Wij gebruiken de beste verwarmingstechnologie die er is en daardoor kunnen wij ook een levenslange garantie geven op de verwarming. Door middel van het hoogwaardige Microwire ® verwarmingssysteem, waarop patent is aangevraagd, zijn het de warmste handschoenen die ooit ontwikkeld zijn. Alle 12 volt verwarmde handschoenen worden geleverd met een accu-aansluitkabel en een in-line junior controller om de warmte van de handschoenen te regelen. Gerbing heeft de volgende typen 12 volt handschoenen in het assortiment: T-12 verwarmde handschoen: Een leren, waterdichte motorhandschoen met bescherming en een mogelijkheid om kleine batterijen te plaatsen (B12V-1400). G-12 verwarmde handschoen: Een basic leren, waterdichte motorhandschoen met een kortere schacht die. De G-12 heeft niet de mogelijkheid om gebruikt te worden in combinatie met kleine batterijen die in de schacht geplaatst kunnen worden. XR-12 verwarmde handschoen: Een leren waterdichte handschoen met extra knokkelbescherming. Net als de T-12 is deze handschoen ook te gebruiken met kleine batterijen. L-12 verwarmde handschoen. Een dunne lycra handschoen die veel gebruikt wordt bij het ultra light vliegen. Deze kan aangesloten worden op de accu van een voertuig maar kan ook aangesloten worden op een draagbare 12 volt batterij zoals de B12V-5200 of de B12V-8000. TEX-12 vewarmde handschoen: Een iets dikkere textiele handschoenen met wat extra gripprotectie aan de binnenkant van de handschoen. Deze kan net als de L-12 aangesloten worden op de accu van een voertuig of op de B12V-5200 of de B12V-8000. De TEX-12 is niet geschikt voor op de motor maar is geweldig voor de brommer, scooter of op de fiets. Al onze 12 volt verwarmde handschoenen zijn te combineren met met al onze andere 12 volt producten zoals de 12 volt verwarmde jas, 12 volt verwarmde broek en 12 volt verwarmde sokken

7V SOKKEN Gerbing staat bekend om zijn verwarmde handschoenen. Zowel de 12 volt verwarmde handschoenen als de 7 volt verwarmde handschoenen zijn algemeen bekend. Sinds kort hebben we echter ook 7 volt verwarmde sokken. Nadat we eerder al de 12 volt verwarmde sokken hebben geïntroduceerd is het nu de beurt aan de 7 volt sokken. De 12 volt sokken moeten aangesloten worden op een accu van een voertuig met behulp van een accukabel. Hierdoor konden mensen die ook bij andere activiteiten last hadden van koude voeten geen gebruik maken van deze geweldige uitvinding. Dankzij de kleine en krachtige 7 volt batterijen met ingebouwde temperatuurregelaar (B7V-2500) is het nu ook mogelijk om bij alle activiteiten er warmpjes bij te lopen. Men kan zelf de gewenste temperatuur instellen door middel van het indrukken van één knop. Dit is de power knop warmee de batterijen ook aangezet kunnen worden. De batterijen gaan op de hoogste temperatuur ongeveer twee tot drie uur mee en op de laagste stand ongeveer zes tot acht uur. Het gepatenteerde micro wire (staaldraad) dat verwerkt is in de sokken is niet voelbaar en verwarmt de hele onderkant van de voeten. De 7 volt verwarmde sokken worden geleverd met een 7 volt batterij KIT (B7V-2500 KIT), deze bestaat uit twee batterijen en één dubbele lader. De batterijen kunnen honderden keren opgeladen worden. De batterijen worden aangesloten op de sokken en door middel van een speciaal ontworpen kuitbandje kun je de batterijen mooi wegwerken. Dankzij deze sokken zullen veel mensen weer kunnen genieten van diverse activiteiten in de buitenlucht. De tijd van koude voeten en bevroren tenen zijn voorbij dankzij de 7 volt verwarmde sokken van Gerbing.

The “Editor’s Choice” and more new products and solutions as described by manufacturers.

Camden Door Controls has released two new publications to support its line of industry-leading locking products, including maglocks, strikes, and cabinet locks.

Prosecutors have secured three convictions against Camden Mayor Justin King over a physical confrontation he began with two victims, as well as his subsequent lack of candor with investigators. King, 41, was until recently the mayor of Camden, Delaware and owns several businesses in the area. On February 25, King confronted two male victims, both […]

Title: Does Remdesivir Work Against COVID-19?
Category: Health News
Created: 8/21/2020 12:00:00 AM
Last Editorial Review: 8/24/2020 12:00:00 AM

Emdeon Reports First Quarter 2010 Results

b"In the clash between tradition and modernity, the courtroom becomes the arena for truth."/b In response to the Supreme Court's criticism regarding

Yogi to judge dancers now!

The government said it's distributing the promising coronavirus drug, remdesivir, to some hard-hit states. Eventually, all 50 states should get it.

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

HHS will ship 14,400 vials of the drug to state health departments, putting the onus on them to decide which hospitals get some of the country's limited supply.

The US Department of Health and Human Services releases an initial plan for the antiviral, but many questions remain.
Medscape Medical News

These are the coronavirus stories you need to know about today.
Medscape Medical News

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

Let this matter be listed in the first week of June, 2020 on a date to be fixed by the Registry. On the next date so fixed, this matter will be taken up for its disposal.

JUDGE Comparing Assistant

The US Department of Health and Human Services announced that it is delivering drug remdesivir to Illinois, New Jersey, Michigan, Connecticut, Maryland and Iowa.

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

An experimental antiviral drug developed by a research-based biopharmaceutical company, Gilead Sciences showed positive results on its application, where more than half of a group of severely ill coronavirus patients improved. UPDATE: On 29 April, Gilead Sciences Inc. announced that in Phase

Researchers use cryo-EM to show how the drug stops RNA replication

Rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site in the United States.; Credit: /AP

Updated at 4:59 p.m. ET

The Food and Drug Administration has given emergency use authorization to the antiviral drug remdesivir to treat hospitalized patients with the coronavirus, President Trump on Friday told reporters at the White House.

Gilead CEO Daniel O'Day said remdesivir maker Gilead Sciences is donating 1.5 million vials of the drug and will work with the federal government to distribute it to patients in need.

The news comes days after preliminary results from a study of the drug showed it can help patients recover faster. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, hailed the findings earlier this week as "quite good news."

The authorization means remdesivir can be distributed in the U.S. and given intravenously to treat COVID-19 patients — both adults and children — who are hospitalized with severe disease, the FDA says. The agency defines that category as "patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator."

Discussing the findings about the drug's ability to help COVID-19 patients, O'Day cautioned earlier Friday that remdesivir is used to treat advanced cases, in which people are already hospitalized. The recent positive findings, he said, are a starting point in the fight against the respiratory disease.

"We want to continue to see how we can expand remdesivir to more patient populations," O'Day said on NBC's Today show. "Clearly with other medicines and vaccines to come, this is part, I think — the beginning of our ability to make an impact on this devastating virus."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.; Credit: Ulrich Perry/POOL/AFP via Getty Images

Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That's when most drugs get price tags.

Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It's unclear when that decision might be made.

"Going forward, we will develop an approach that is guided by the principles of affordability and access," Gilead CEO Daniel O'Day told shareholders during the company's annual meeting Wednesday.

In a quarterly financial filing made the same day, Gilead said its investment in remdesivir this year "could be up to $1 billion or more," much of it for scaling up manufacturing capacity.

The company also acknowledged that it's in the spotlight. "[G]iven that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we are likely to face significant public attention and scrutiny about any future business models and pricing decisions with respect to remdesivir," Gilead said in the quarterly filing.

How will the company balance its business calculations with the drug's potential value to society?

"Gilead has not yet set a price for remdesivir," company spokeswoman Sonia Choi wrote in an email to NPR. "At this time, we are focused on ensuring access to remdesivir through our donation. Post-donation, we are committed to making remdesivir both accessible and affordable to governments and patients around the world."

Among potential treatments for COVID-19, remdesivir, an intravenous drug that was once studied for Ebola, is one of the furthest along.

"It's hard to imagine a situation in which there will be more public scrutiny," said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. "On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what's viewed as too high a price."

Breaking with its usual practices, the Institute for Clinical and Economic Review, or ICER, an influential nonprofit that analyzes drug pricing, issued an expedited report on remdesivir.

"Under normal circumstances, we would be unlikely to do a report when the evidence is this raw and immature," ICER President Steven Pearson said in an interview with NPR. "But it was quite clear that the world is moving at a much quicker pace."

If the price is based just on the cost of making the drug, then a 10-day course of remdesivir should cost about $10, according to the ICER report. (Gilead said results of a recently completed study suggest a five-day course of treatment may be just as effective.)

But if the drug is priced based on the drug's effectiveness, ICER estimates it should cost around $4,500 — assuming the drug is proven to have some benefit on mortality. If it doesn't and the drug only shortens hospital stays, that value-based price goes down to $390.

Results from a federally funded study described by Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, suggested that remdesvir could reduce recovery time by a median of four days — 11 days to recovery for patients treated with remdesivir compared with 15 days for those who got a placebo. A potential survival benefit is less clear.

Rutgers's Carrier said he expects Gilead to set the remdesivir price somewhere between the $10 and $4,500 that ICER estimated. The company has already shown that it can respond to public pressure when it asked the FDA to rescind the orphan drug status it won for remdesivir, he pointed out.

"When you see that $10 figure, that sets a benchmark for a figure that is eminently affordable," Carrier said. Ultimately, he said a price more than $1,000 per treatment course would be unpopular.

Gilead "will be watched very carefully," he said, because of its prior history of pricing. He referred to two other Gilead drugs that drew scrutiny over high price tags. The company charged $1,000 per pill for Sovaldi, a cure for hepatitis C. And its HIV drug Truvada can cost $22,000 per year.

But there is such a thing as pricing remdesivir too low, said Craig Garthwaite, who directs the health care program at Northwestern University's Kellogg School of Management.

"We don't think this is the only drug we need," he said, adding that remdesivir doesn't appear to be a "home run" against the coronavirus, based on existing data. "The thing that would worry me the most is that we're somehow telling people that if you take the risky bet to try, and you'll go after a coronavirus cure and you do it, you're not going to get paid."

Instead, he said he would like to see acceptance of a generous price for remdesivir to send the message to drug companies that the best thing they can do is "dedicate every waking moment to trying to develop that cure, and that if they do that, we will pay them the value they create," he said.

During a Gilead earnings call on April 30, analysts asked executives whether they could expect similar financial returns on remdesivir as they've seen with Gilead's other drugs.

"There is no rulebook out there, other than that we need to be very thoughtful about how we can make sure we provide access of our medicines to patients around the globe," Gilead CEO O'Day said. "And do that in a sustainable way for the company, for ... shareholders, and we acknowledge that."

On May 1, the FDA authorized remdesivir for emergency use, meaning it will be easier to administer to hospitalized patients with severe disease during the pandemic, but the drug is not yet officially approved. The federal government is coordinating distribution of the treatment.

Day acknowledged on the recent earnings call that the company "could" charge for remdesivir under an emergency use authorization, but he stressed that Gilead is donating its current supply, which should last through "early summer."

To date, the National Institutes of Health said it has obligated $23 million toward its COVID-19 remdesivir trial. And the U.S. Army Medical Research Institute of Infectious Diseases did some of the early in vitro and animal studies with the medicine prior to the pandemic.

"Taxpayers are often the angel investors in pharmaceutical research and development, yet this is not reflected in the prices they pay," Reps. Lloyd Doggett, D-Texas, and Rosa DeLauro, D-Conn., wrote in a April 30 letter to Health and Human Services Secretary Alex Azar.

Concerned about remdesivir's price, they asked for a full breakdown of taxpayer funds that have gone toward the development of the medicine. "An unaffordable drug is completely ineffective," they wrote in the letter. "The substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.; Credit: Ulrich Perry/POOL/AFP via Getty Images

Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That's when most drugs get price tags.

Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It's unclear when that decision might be made.

"Going forward, we will develop an approach that is guided by the principles of affordability and access," Gilead CEO Daniel O'Day told shareholders during the company's annual meeting Wednesday.

In a quarterly financial filing made the same day, Gilead said its investment in remdesivir this year "could be up to $1 billion or more," much of it for scaling up manufacturing capacity.

The company also acknowledged that it's in the spotlight. "[G]iven that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we are likely to face significant public attention and scrutiny about any future business models and pricing decisions with respect to remdesivir," Gilead said in the quarterly filing.

How will the company balance its business calculations with the drug's potential value to society?

"Gilead has not yet set a price for remdesivir," company spokeswoman Sonia Choi wrote in an email to NPR. "At this time, we are focused on ensuring access to remdesivir through our donation. Post-donation, we are committed to making remdesivir both accessible and affordable to governments and patients around the world."

Among potential treatments for COVID-19, remdesivir, an intravenous drug that was once studied for Ebola, is one of the furthest along.

"It's hard to imagine a situation in which there will be more public scrutiny," said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. "On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what's viewed as too high a price."

Breaking with its usual practices, the Institute for Clinical and Economic Review, or ICER, an influential nonprofit that analyzes drug pricing, issued an expedited report on remdesivir.

"Under normal circumstances, we would be unlikely to do a report when the evidence is this raw and immature," ICER President Steven Pearson said in an interview with NPR. "But it was quite clear that the world is moving at a much quicker pace."

If the price is based just on the cost of making the drug, then a 10-day course of remdesivir should cost about $10, according to the ICER report. (Gilead said results of a recently completed study suggest a five-day course of treatment may be just as effective.)

But if the drug is priced based on the drug's effectiveness, ICER estimates it should cost around $4,500 — assuming the drug is proven to have some benefit on mortality. If it doesn't and the drug only shortens hospital stays, that value-based price goes down to $390.

Results from a federally funded study described by Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, suggested that remdesvir could reduce recovery time by a median of four days — 11 days to recovery for patients treated with remdesivir compared with 15 days for those who got a placebo. A potential survival benefit is less clear.

Rutgers's Carrier said he expects Gilead to set the remdesivir price somewhere between the $10 and $4,500 that ICER estimated. The company has already shown that it can respond to public pressure when it asked the FDA to rescind the orphan drug status it won for remdesivir, he pointed out.

"When you see that $10 figure, that sets a benchmark for a figure that is eminently affordable," Carrier said. Ultimately, he said a price more than $1,000 per treatment course would be unpopular.

Gilead "will be watched very carefully," he said, because of its prior history of pricing. He referred to two other Gilead drugs that drew scrutiny over high price tags. The company charged $1,000 per pill for Sovaldi, a cure for hepatitis C. And its HIV drug Truvada can cost $22,000 per year.

But there is such a thing as pricing remdesivir too low, said Craig Garthwaite, who directs the health care program at Northwestern University's Kellogg School of Management.

"We don't think this is the only drug we need," he said, adding that remdesivir doesn't appear to be a "home run" against the coronavirus, based on existing data. "The thing that would worry me the most is that we're somehow telling people that if you take the risky bet to try, and you'll go after a coronavirus cure and you do it, you're not going to get paid."

Instead, he said he would like to see acceptance of a generous price for remdesivir to send the message to drug companies that the best thing they can do is "dedicate every waking moment to trying to develop that cure, and that if they do that, we will pay them the value they create," he said.

During a Gilead earnings call on April 30, analysts asked executives whether they could expect similar financial returns on remdesivir as they've seen with Gilead's other drugs.

"There is no rulebook out there, other than that we need to be very thoughtful about how we can make sure we provide access of our medicines to patients around the globe," Gilead CEO O'Day said. "And do that in a sustainable way for the company, for ... shareholders, and we acknowledge that."

On May 1, the FDA authorized remdesivir for emergency use, meaning it will be easier to administer to hospitalized patients with severe disease during the pandemic, but the drug is not yet officially approved. The federal government is coordinating distribution of the treatment.

Day acknowledged on the recent earnings call that the company "could" charge for remdesivir under an emergency use authorization, but he stressed that Gilead is donating its current supply, which should last through "early summer."

To date, the National Institutes of Health said it has obligated $23 million toward its COVID-19 remdesivir trial. And the U.S. Army Medical Research Institute of Infectious Diseases did some of the early in vitro and animal studies with the medicine prior to the pandemic.

"Taxpayers are often the angel investors in pharmaceutical research and development, yet this is not reflected in the prices they pay," Reps. Lloyd Doggett, D-Texas, and Rosa DeLauro, D-Conn., wrote in a April 30 letter to Health and Human Services Secretary Alex Azar.

Concerned about remdesivir's price, they asked for a full breakdown of taxpayer funds that have gone toward the development of the medicine. "An unaffordable drug is completely ineffective," they wrote in the letter. "The substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized."

This content is from Southern California Public Radio. View the original story at SCPR.org.

AP Photo/Alex Brandon

• The federal government on Saturday announced initial plans for distributing a promising coronavirus drug, remdesivir.
• The drug, manufactured by Gilead Sciences, was authorized for emergency use last week, but doctors and hospitals weren't sure how they were going to get it.
• The Department of Health and Human Services now say the drug is first being distributed to health departments in some hard-hit states, and the departments can distribute it to hospitals as they see fit. 
• Eventually, HHS expects the drug to be delivered to all 50 states, terrorities, the Veterans Health Administration and the Indian Health Service. 
• Visit Business Insider's homepage for more stories.

The federal government released its initial distribution plans today for the promising coronavirus drug, remdesivir, which was approved for emergency use last week. 

The drug, donated by manufacturer Gilead Sciences, "will be used to treat hospitalized COVID-19 patients in areas of the country hardest hit by the pandemic," the US Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) said in a press release.

See the rest of the story at Business Insider

NOW WATCH: How the Navy's largest hospital ship can help with the coronavirus

See Also:

• The coronavirus drug remdesivir was OK'd for emergency use a week ago. The plan to get it to patients is still mired in confusion.
• Dispensed: Hospitals are stuck waiting for a promising coronavirus treatment
• 'It's hard to pay off your medical school loans in this kind of a job': Doctors who can protect the world against pandemics are in short supply

Steven Wood writes: There now some controversy regarding the effectiveness of Remdesivir for treatment of Covid. With the inadvertent posting of results on the WHO website. https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/ One of the pillars of hope for this treatment is the monkey treatment trial (the paper is here). As an experience clinical trialist I was immediately skeptical of […]

The union representing 700 hospitality workers at Camden Yards is asking for financial help on what would have been opening day.

Retail in India has not developed at the same pace as the products. Getting good quality retail is a challenge. The country has limited number of malls. There is no high street.

Wir müssen uns vorerst von der Hoffnung verabschieden, weit weg zu fahren, um den Alltag und alles Negative hinter uns zu lassen. Was macht das mit uns? Wie können wir uns trotzdem erholen? Eine Psychologin gibt Tipps.

http://www.musicxray.com/xrays/1319815 HUNNAFIEDRECORDS - COCA KAZI -Camden

http://www.musicxray.com/xrays/1319837 COCA-KAZI -HUNNAFIEDRECORDS - Camden

On today's show: * What's remdesivir? * Where does it come from? * What do we know about side effects? * What about that study from China that found it provided no benefit? * Is lifting restrictions now too risky? * What does all the research into SARS-CoV-2 mean for the common cold?

The foxy hornbags get tizzy with a big screen adventure that's filled with noice jokes but a stew-pid storyline.

Look at moiye! Kath and Kim are back!

Last week, the US announced approval to use a drug named remdesivir, made by Gilead, in people sick with COVID-19.

Japan reaches the decision to approve the antiviral medication previously used to treat Ebola patients just three days after the drugmaker filed for approval.

The goal: Let everyone play with many different TypeScript features and get an overview of TypeScript capabilities and principles.

You may recall in the early days of the pandemic, that pharma giant Gilead Sciences -- which has been accused of price gouging and (just last year!) charging exorbitant prices on drug breakthroughs developed with US taxpayer funds -- was able to sneak through an orphan works designation for its drug remdesevir for COVID-19 treatment. As we pointed out, everything about this was insane, given that orphan works designations, which give extra monopoly rights to the holders (beyond patent exclusivity), are meant for diseases that don't impact a large population. Gilead used a loophole: since the ceiling for infected people to qualify for orphan drug status is 200,000, Gilead got in its application bright and early, before there were 200,000 confirmed cases (we currently have over 1.3 million). After the story went, er... viral, Gilead agreed to drop the orphan status, realizing the bad publicity it was receiving.

After a brief dalliance with chloroquine, remdesivir has suddenly been back in demand as the new hotness of possible COVID-19 treatments. Still, a close reading of the research might give one pause. There have been multiple conflicting studies, and Gilead's own messaging has been a mess.

On April 23, 2020, news of the study’s failure began to circulate. It seems that the World Health Organization (WHO) had posted a draft report about the trial on their clinical trials database, which indicated that the scientists terminated the study prematurely due to high levels of adverse side effects.

The WHO withdrew the report, and the researchers published their results in The Lancet on April 29, 2020.

The number of people who experienced adverse side effects was roughly similar between those receiving remdesivir and those receiving a placebo. In 18 participants, the researchers stopped the drug treatment due to adverse reactions.

But then...

However, also on April 29, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that their NIH trial showed that remdesivir treatment led to faster recovery in hospital patients with COVID-19, compared with placebo treatment.

“Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo,” according to the press release. “Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo.”

The mortality rate in the remdesivir treatment group was 8%, compared with 11.6% in the placebo group, indicating that the drug could improve a person’s chances of survival. These data were close to achieving statistical significance.

And then...

“In addition, there is another Chinese trial, also stopped because the numbers of new patients with COVID-19 had fallen in China so they were unable to recruit, which has not yet published its data,” Prof. Evans continues. “There are other trials where remdesivir is compared with non-remdesivir treatments currently [being] done and results from some of these should appear soon.”

Gilead also put out its own press release about another clinical trial, which seems more focused on determining the optimal length of remdesivir treatment. Suffice it to say, there's still a lot of conflicting data and no clear information on whether or not remdesevir actually helps.

Still, that hasn't stopped people from trying to figure out just how much Gilead will price gouge going forward:

The Institute for Clinical and Economic Review (ICER), which assesses effectiveness of drugs to determine appropriate prices, suggested a maximum price of $4,500 per 10-day treatment course based on the preliminary evidence of how much patients benefited in a clinical trial. Consumer advocacy group Public Citizen on Monday said remdesivir should be priced at $1 per day of treatment, since “that is more than the cost of manufacturing at scale with a reasonable profit to Gilead.”

Some Wall Street investors expect Gilead to come in at $4,000 per patient or higher to make a profit above remdesivir’s development cost, which Gilead estimates at about $1 billion.

So... we've got a range of $10 to $4,500 on a treatment that we don't yet know works, and which may or may not save lives. But, given that we're in the midst of a giant debate concerning things like "reopening the economy" -- something that can really only be done if the public is not afraid of dying (or at least becoming deathly ill) -- the value to the overall economy seems much greater than whatever amount Gilead wants to charge. It seems the right thing to do -- again, if it's shown that remdesevir actually helps -- is to just hand over a bunch of money to Gilead, say "thank you very much" and get the drug distributed as widely as possible. Though, again, it should be noted that a decent chunk of the research around remdesevir was not done or paid for by Gilead, but (yet again) via public funds to public universities, which did the necessary research. The idea that it's Gilead that should get to reap massive rewards for that seems sketchy at best. But the absolute worst outcome is one in which Gilead sticks to its standard operating procedure and prices the drug in a way that millions of Americans can't afford it, and it leads to a prolonging/expanding of the pandemic.

NIH clinical trial testing antiviral remdesivir plus anti-inflammatory drug baricitinib for COVID-19 begins  National Institutes of HealthView Full coverage on Google News

A preliminary report on patients infected with the coronavirus suggests the drug remdesivir may lower the risk of death in those with severe cases of COVID-19.

The data on its effect on symptoms comes from a trial of more than 1,000 patients in the US.

The Food and Drug Administration authorises emergency use of the experimental anti-viral drug.

(NIH/National Institute of Allergy and Infectious Diseases) A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for COVID-19 has begun. The trial is now enrolling hospitalized adults with COVID-19 in the United States. The trial is expected to open at approximately 100 US and international sites. Investigators currently anticipate enrolling more than 1,000 participants. The National Institute of Allergy and Infectious Diseases is sponsoring the trial.